NewsXbrane Biopharma clarifies information regarding letter of intent with CR Pharma considering Xlucane

Xbrane Biopharma (“Xbrane” or the “Company”) signed the 7th of December 2017 a non-binding letter of intent with the Chinese pharmaceutical company CR Pharma regarding out-licensing of Xlucane for the Chinese market.

 It has come to our attention that CR Pharma has on its website published news about a collaboration with Xbrane regarding Xlucane and Xbrane hereby clarifies the situation. Xbrane and CR Pharma has the joint intention to take Xlucane, a ranibizumab biosimilar, to the Chinese market. A non-binding letter of intent has been signed but no terms has yet been agreed. A detailed evaluation of the product, market and local regulatory requirements will now follow along with negotiations regarding commercial terms for a potential final agreement. CR Pharma is also the company with which Xbrane, as per previous communication, is finalizing an out-licensing agreement regarding Spherotide.

Being a non-binding letter of intent, Xbrane has not considered this information of such character that the company needs to communicate in order to fulfil its requirements within MAR regulation. If and when a final agreement has been signed Xbrane will inform the market.

For further information, please contact:
Martin Åmark, CEO, Xbrane Biopharma AB
M: +46 (0) 763-093 777
E: martin.amark@xbrane.com 

Susanna Helgesen, CFO/IR, Xbrane Biopharma AB
M: +46 (0) 708-278 636
E: susanna.helgesen@xbrane.com